Disagreement in normative IGF‐I levels may lead to different clinical interpretations and GH dose adjustments in GH deficiency

Summary Introduction and Background Normative data for the iSYS IGF‐I assay have been published both in the VARIETE cohort and by Bidlingmaier et al. Objective To investigate whether normative data of the VARIETE cohort lead to differences in Z‐scores for total IGF‐I and clinical interpretation comp...

Full description

Saved in:
Bibliographic Details
Published inClinical endocrinology (Oxford) Vol. 88; no. 3; pp. 409 - 414
Main Authors Varewijck, A.J., van der Lely, A.J., Neggers, S.J.C.M.M., Hofland, L.J., Janssen, J.A.M.J.L.
Format Journal Article
LanguageEnglish
Published England Wiley Subscription Services, Inc 01.03.2018
Subjects
Online AccessGet full text
ISSN0300-0664
1365-2265
1365-2265
DOI10.1111/cen.13491

Cover

Abstract Summary Introduction and Background Normative data for the iSYS IGF‐I assay have been published both in the VARIETE cohort and by Bidlingmaier et al. Objective To investigate whether normative data of the VARIETE cohort lead to differences in Z‐scores for total IGF‐I and clinical interpretation compared to normative data of Bidlingmaier et al. Design We used total IGF‐I values previously measured by the IDS‐iSYS assay in 102 GH‐deficient subjects before starting GH treatment and after 12 months of GH treatment. Z‐scores were calculated for all samples by using the normative data of the VARIETE cohort and by the normative data reported by Bidlingmaier et al. Result Before GH treatment, Z‐scores calculated by using the normative data of the VARIETE cohort were significantly lower than those calculated by the normative data of Bidlingmaier et al: −2.40 (−4.52 to +1.31) (mean [range]) vs. −1.41 (−3.14 to +1.76); P < .001). After 12 months of GH treatment, again the Z‐scores based on the normative data of the VARIETE cohort were significantly lower than those based on the normative data of Bidlingmaier et al: −0.65 (−4.32 to +2.79) vs 0.21 (−3.00 to +3.28); P < .001). Conclusion IGF‐I Z‐scores in 102 GH‐deficient subjects differed significantly when normative data from two different sources were used. In daily clinical practice, this would most likely have led to different clinical interpretations and GH dose adjustments.
AbstractList Summary Introduction and Background Normative data for the iSYS IGF‐I assay have been published both in the VARIETE cohort and by Bidlingmaier et al. Objective To investigate whether normative data of the VARIETE cohort lead to differences in Z‐scores for total IGF‐I and clinical interpretation compared to normative data of Bidlingmaier et al. Design We used total IGF‐I values previously measured by the IDS‐iSYS assay in 102 GH‐deficient subjects before starting GH treatment and after 12 months of GH treatment. Z‐scores were calculated for all samples by using the normative data of the VARIETE cohort and by the normative data reported by Bidlingmaier et al. Result Before GH treatment, Z‐scores calculated by using the normative data of the VARIETE cohort were significantly lower than those calculated by the normative data of Bidlingmaier et al: −2.40 (−4.52 to +1.31) (mean [range]) vs. −1.41 (−3.14 to +1.76); P < .001). After 12 months of GH treatment, again the Z‐scores based on the normative data of the VARIETE cohort were significantly lower than those based on the normative data of Bidlingmaier et al: −0.65 (−4.32 to +2.79) vs 0.21 (−3.00 to +3.28); P < .001). Conclusion IGF‐I Z‐scores in 102 GH‐deficient subjects differed significantly when normative data from two different sources were used. In daily clinical practice, this would most likely have led to different clinical interpretations and GH dose adjustments.
Summary Introduction and Background Normative data for the iSYS IGF-I assay have been published both in the VARIETE cohort and by Bidlingmaier et al. Objective To investigate whether normative data of the VARIETE cohort lead to differences in Z-scores for total IGF-I and clinical interpretation compared to normative data of Bidlingmaier et al. Design We used total IGF-I values previously measured by the IDS-iSYS assay in 102 GH-deficient subjects before starting GH treatment and after 12 months of GH treatment. Z-scores were calculated for all samples by using the normative data of the VARIETE cohort and by the normative data reported by Bidlingmaier et al. Result Before GH treatment, Z-scores calculated by using the normative data of the VARIETE cohort were significantly lower than those calculated by the normative data of Bidlingmaier et al: -2.40 (-4.52 to +1.31) (mean [range]) vs. -1.41 (-3.14 to +1.76); P < .001). After 12 months of GH treatment, again the Z-scores based on the normative data of the VARIETE cohort were significantly lower than those based on the normative data of Bidlingmaier et al: -0.65 (-4.32 to +2.79) vs 0.21 (-3.00 to +3.28); P < .001). Conclusion IGF-I Z-scores in 102 GH-deficient subjects differed significantly when normative data from two different sources were used. In daily clinical practice, this would most likely have led to different clinical interpretations and GH dose adjustments.
Normative data for the iSYS IGF-I assay have been published both in the VARIETE cohort and by Bidlingmaier et al. To investigate whether normative data of the VARIETE cohort lead to differences in Z-scores for total IGF-I and clinical interpretation compared to normative data of Bidlingmaier et al. We used total IGF-I values previously measured by the IDS-iSYS assay in 102 GH-deficient subjects before starting GH treatment and after 12 months of GH treatment. Z-scores were calculated for all samples by using the normative data of the VARIETE cohort and by the normative data reported by Bidlingmaier et al. Before GH treatment, Z-scores calculated by using the normative data of the VARIETE cohort were significantly lower than those calculated by the normative data of Bidlingmaier et al: -2.40 (-4.52 to +1.31) (mean [range]) vs. -1.41 (-3.14 to +1.76); P < .001). After 12 months of GH treatment, again the Z-scores based on the normative data of the VARIETE cohort were significantly lower than those based on the normative data of Bidlingmaier et al: -0.65 (-4.32 to +2.79) vs 0.21 (-3.00 to +3.28); P < .001). IGF-I Z-scores in 102 GH-deficient subjects differed significantly when normative data from two different sources were used. In daily clinical practice, this would most likely have led to different clinical interpretations and GH dose adjustments.
Normative data for the iSYS IGF-I assay have been published both in the VARIETE cohort and by Bidlingmaier et al.INTRODUCTION AND BACKGROUNDNormative data for the iSYS IGF-I assay have been published both in the VARIETE cohort and by Bidlingmaier et al.To investigate whether normative data of the VARIETE cohort lead to differences in Z-scores for total IGF-I and clinical interpretation compared to normative data of Bidlingmaier et al.OBJECTIVETo investigate whether normative data of the VARIETE cohort lead to differences in Z-scores for total IGF-I and clinical interpretation compared to normative data of Bidlingmaier et al.We used total IGF-I values previously measured by the IDS-iSYS assay in 102 GH-deficient subjects before starting GH treatment and after 12 months of GH treatment. Z-scores were calculated for all samples by using the normative data of the VARIETE cohort and by the normative data reported by Bidlingmaier et al.DESIGNWe used total IGF-I values previously measured by the IDS-iSYS assay in 102 GH-deficient subjects before starting GH treatment and after 12 months of GH treatment. Z-scores were calculated for all samples by using the normative data of the VARIETE cohort and by the normative data reported by Bidlingmaier et al.Before GH treatment, Z-scores calculated by using the normative data of the VARIETE cohort were significantly lower than those calculated by the normative data of Bidlingmaier et al: -2.40 (-4.52 to +1.31) (mean [range]) vs. -1.41 (-3.14 to +1.76); P < .001). After 12 months of GH treatment, again the Z-scores based on the normative data of the VARIETE cohort were significantly lower than those based on the normative data of Bidlingmaier et al: -0.65 (-4.32 to +2.79) vs 0.21 (-3.00 to +3.28); P < .001).RESULTBefore GH treatment, Z-scores calculated by using the normative data of the VARIETE cohort were significantly lower than those calculated by the normative data of Bidlingmaier et al: -2.40 (-4.52 to +1.31) (mean [range]) vs. -1.41 (-3.14 to +1.76); P < .001). After 12 months of GH treatment, again the Z-scores based on the normative data of the VARIETE cohort were significantly lower than those based on the normative data of Bidlingmaier et al: -0.65 (-4.32 to +2.79) vs 0.21 (-3.00 to +3.28); P < .001).IGF-I Z-scores in 102 GH-deficient subjects differed significantly when normative data from two different sources were used. In daily clinical practice, this would most likely have led to different clinical interpretations and GH dose adjustments.CONCLUSIONIGF-I Z-scores in 102 GH-deficient subjects differed significantly when normative data from two different sources were used. In daily clinical practice, this would most likely have led to different clinical interpretations and GH dose adjustments.
Author Hofland, L.J.
Janssen, J.A.M.J.L.
van der Lely, A.J.
Neggers, S.J.C.M.M.
Varewijck, A.J.
Author_xml – sequence: 1
  givenname: A.J.
  surname: Varewijck
  fullname: Varewijck, A.J.
  organization: Erasmus MC
– sequence: 2
  givenname: A.J.
  surname: van der Lely
  fullname: van der Lely, A.J.
  organization: Erasmus MC
– sequence: 3
  givenname: S.J.C.M.M.
  surname: Neggers
  fullname: Neggers, S.J.C.M.M.
  organization: Erasmus MC
– sequence: 4
  givenname: L.J.
  surname: Hofland
  fullname: Hofland, L.J.
  organization: Erasmus MC
– sequence: 5
  givenname: J.A.M.J.L.
  orcidid: 0000-0002-9363-6408
  surname: Janssen
  fullname: Janssen, J.A.M.J.L.
  email: j.a.m.j.l.janssen@erasmusmc.nl
  organization: Erasmus MC
BackLink https://www.ncbi.nlm.nih.gov/pubmed/28977695$$D View this record in MEDLINE/PubMed
BookMark eNp9kc1u1DAUhS1URKeFBS-ALLGBRVr_JE6yREM7HamCDawtx75GHjn2YCetZtdH4Bl5EhymsKgE3lzL-s49vvecoZMQAyD0mpILWs6lhnBBed3TZ2hFuWgqxkRzglaEE1IRIepTdJbzjhDSdKR9gU5Z17et6JsVevjosvqWAEYIE3YBh5hGNbk7wNvN9c-HH1vs4Q58xqM6lKsyeIrYOGshLQrtXXBa-SKdIO0TTEUcQ8YqGLy5wSZmwMrs5jwtDnmxWJ7BOu0g6MNL9Nwqn-HVYz1HX6-vvqxvqtvPm-36w22lecNpNQirzNAPigPjxtTQKkUYZYbbxlpKO8FrC6RtOADrtaVDmR16bojpaCsafo7eHfvuU_w-Q57k6LIG71WAOGdJ-7oVjNQdLejbJ-guzimU30lGiqnoe0YK9eaRmocRjNwnN6p0kH92W4D3R0CnmHMC-xehRC65yZKb_J1bYS-fsNodNzkl5fz_FPfOw-HfreX66tNR8Qt4TKn3
CitedBy_id crossref_primary_10_1111_cen_15000
crossref_primary_10_1016_j_heliyon_2024_e38245
crossref_primary_10_1080_10408363_2024_2306804
crossref_primary_10_1210_clinem_dgac157
crossref_primary_10_1159_000493133
crossref_primary_10_1210_jc_2018_01979
crossref_primary_10_1016_j_clinbiochem_2023_02_008
crossref_primary_10_1016_j_ghir_2019_12_001
Cites_doi 10.1210/jc.2016-1257
10.1093/ajcn/70.1.163s
10.1016/j.ghir.2009.02.002
10.1210/jc.2013-3059
10.1136/adc.2005.081216
10.1007/s00431-007-0565-1
10.1373/clinchem.2010.150631
10.1007/s13312-014-0310-6
10.1002/uog.3911
10.1002/sim.4780111005
10.1210/jcem.83.11.5223
10.1210/jc.81.4.1371
10.1179/acb.2006.053
10.1016/j.clinbiochem.2007.06.004
10.1016/j.ecl.2014.10.003
10.1210/jc.2009-2139
10.1111/j.1471-0528.1994.tb13006.x
10.1210/jc.2012-2901
10.1159/000063484
10.1530/EJE-09-0247
10.4158/EP.15.S2.1
10.1159/000087692
10.1159/000178034
10.1159/000071871
10.2307/2982992
10.1002/sim.1692
10.1210/jc.2014-2558
10.1515/CCLM.2008.349
10.1016/j.ejogrb.2012.04.013
10.1002/sim.2227
10.1507/endocrj.K09E-200
ContentType Journal Article
Copyright 2017 John Wiley & Sons Ltd
2017 John Wiley & Sons Ltd.
Copyright © 2018 John Wiley & Sons Ltd
Copyright_xml – notice: 2017 John Wiley & Sons Ltd
– notice: 2017 John Wiley & Sons Ltd.
– notice: Copyright © 2018 John Wiley & Sons Ltd
DBID AAYXX
CITATION
NPM
7QP
K9.
NAPCQ
7X8
DOI 10.1111/cen.13491
DatabaseName CrossRef
PubMed
Calcium & Calcified Tissue Abstracts
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Premium
MEDLINE - Academic
DatabaseTitle CrossRef
PubMed
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Premium
Calcium & Calcified Tissue Abstracts
MEDLINE - Academic
DatabaseTitleList
ProQuest Health & Medical Complete (Alumni)
PubMed
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1365-2265
EndPage 414
ExternalDocumentID 28977695
10_1111_cen_13491
CEN13491
Genre article
Journal Article
GroupedDBID ---
.3N
.55
.GA
.GJ
.Y3
05W
08P
0R~
10A
1OB
1OC
29B
31~
33P
36B
3O-
3SF
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5GY
5HH
5LA
5RE
5VS
66C
6J9
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHHS
AAHQN
AAIPD
AAKAS
AAMNL
AANHP
AANLZ
AAONW
AAQQT
AASGY
AAXRX
AAYCA
AAZKR
ABCQN
ABCUV
ABEML
ABJNI
ABPVW
ABQWH
ABXGK
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACGFO
ACGFS
ACGOF
ACMXC
ACPOU
ACPRK
ACRPL
ACSCC
ACXBN
ACXQS
ACYXJ
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADNMO
ADOZA
ADXAS
ADZCM
ADZMN
ADZOD
AEEZP
AEGXH
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFEBI
AFFNX
AFFPM
AFGKR
AFPWT
AFWVQ
AFZJQ
AHBTC
AHEFC
AHMBA
AIACR
AIAGR
AITYG
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMBMR
AMYDB
ASPBG
ATUGU
AVWKF
AZBYB
AZFZN
AZVAB
BAFTC
BDRZF
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BY8
C45
CAG
COF
CS3
D-6
D-7
D-E
D-F
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
DUUFO
EBS
EJD
EMOBN
ESX
EX3
F00
F01
F04
F5P
FEDTE
FUBAC
FZ0
G-S
G.N
GODZA
H.X
HF~
HGLYW
HVGLF
HZI
HZ~
IHE
IX1
J0M
J5H
K48
KBYEO
LATKE
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
MEWTI
MJL
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
O66
O9-
OIG
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
PALCI
PQQKQ
Q.N
Q11
QB0
R.K
REN
RIWAO
RJQFR
ROL
RX1
SAMSI
SUPJJ
TEORI
UB1
V8K
W8V
W99
WBKPD
WHWMO
WIH
WIJ
WIK
WOHZO
WOW
WQJ
WRC
WUP
WVDHM
WXI
WXSBR
X7M
XG1
YOC
YUY
ZGI
ZXP
ZZTAW
~IA
~WT
AAMMB
AAYXX
AEFGJ
AEYWJ
AGHNM
AGQPQ
AGXDD
AGYGG
AIDQK
AIDYY
AIQQE
CITATION
NPM
7QP
K9.
NAPCQ
7X8
ID FETCH-LOGICAL-c3531-b6fadb9ba3e23dd4e7aa0212d3f5ff118634fe0753ee29cf1b300e93d0d817653
IEDL.DBID DR2
ISSN 0300-0664
1365-2265
IngestDate Tue Aug 05 11:02:05 EDT 2025
Mon Oct 06 18:03:24 EDT 2025
Wed Feb 19 02:36:40 EST 2025
Wed Oct 01 02:17:12 EDT 2025
Thu Apr 24 22:58:42 EDT 2025
Wed Jan 22 17:11:39 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 3
Keywords GH deficiency
clinical interpretation
IGF-I
normative data
LMS method
Language English
License http://onlinelibrary.wiley.com/termsAndConditions#vor
2017 John Wiley & Sons Ltd.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c3531-b6fadb9ba3e23dd4e7aa0212d3f5ff118634fe0753ee29cf1b300e93d0d817653
Notes Funding information
This research did not receive any specific grant from any funding agency in the public, commercial or not‐for‐profit sector.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0002-9363-6408
PMID 28977695
PQID 2002169920
PQPubID 36523
PageCount 6
ParticipantIDs proquest_miscellaneous_1947620481
proquest_journals_2002169920
pubmed_primary_28977695
crossref_primary_10_1111_cen_13491
crossref_citationtrail_10_1111_cen_13491
wiley_primary_10_1111_cen_13491_CEN13491
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate March 2018
2018-03-00
20180301
PublicationDateYYYYMMDD 2018-03-01
PublicationDate_xml – month: 03
  year: 2018
  text: March 2018
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
– name: Oxford
PublicationTitle Clinical endocrinology (Oxford)
PublicationTitleAlternate Clin Endocrinol (Oxf)
PublicationYear 2018
Publisher Wiley Subscription Services, Inc
Publisher_xml – name: Wiley Subscription Services, Inc
References 2012; 163
2010; 57
2015; 100
2004; 23
2016; 101
2005; 64
2007
2007; 92
2011; 57
1998; 83
2008; 167
1992; 11
1994; 101
2007; 29
1990; 44
2006; 61
2013; 98
2009; 71
2015; 44
2006; 25
2008; 46
2009; 161
1996; 81
2007; 40
1988; 151
2001; 55
2003; 60
2009; 19
2014; 51
1999; 70
2010; 95
2014; 99
2009; 15
e_1_2_6_32_1
e_1_2_6_31_1
e_1_2_6_30_1
Anckaert E (e_1_2_6_10_1) 2006; 61
Cole TJ (e_1_2_6_21_1) 1990; 44
e_1_2_6_19_1
van Buuren S (e_1_2_6_27_1) 2007
Varewijck AJ (e_1_2_6_16_1) 2015; 100
e_1_2_6_13_1
e_1_2_6_14_1
e_1_2_6_11_1
e_1_2_6_34_1
e_1_2_6_12_1
e_1_2_6_33_1
e_1_2_6_17_1
e_1_2_6_18_1
e_1_2_6_15_1
e_1_2_6_20_1
Garagorri JM (e_1_2_6_24_1) 2008; 167
e_1_2_6_9_1
e_1_2_6_8_1
e_1_2_6_5_1
e_1_2_6_4_1
e_1_2_6_7_1
e_1_2_6_6_1
e_1_2_6_25_1
e_1_2_6_3_1
e_1_2_6_23_1
e_1_2_6_2_1
e_1_2_6_22_1
e_1_2_6_29_1
e_1_2_6_28_1
e_1_2_6_26_1
References_xml – volume: 57
  start-page: 221
  year: 2010
  end-page: 228
  article-title: Reference ranges for serum IGF‐1 and IGFBP‐3 levels in Chinese children during childhood and adolescence
  publication-title: Endocr J
– volume: 101
  start-page: 3450
  year: 2016
  end-page: 3458
  article-title: Reference values for IGF‐I serum concentrations: comparison of six immunoassays
  publication-title: J Clin Endocrinol Metab
– volume: 25
  start-page: 247
  year: 2006
  end-page: 265
  article-title: Construction of the World Health Organization child growth standards: selection of methods for attained growth curves
  publication-title: Stat Med
– volume: 101
  start-page: 29
  year: 1994
  end-page: 34
  article-title: Charts of fetal size: 1. Methodology
  publication-title: Br J Obstet Gynaecol
– volume: 46
  start-page: 1776
  year: 2008
  end-page: 1783
  article-title: Five commercially available insulin‐like growth factor I (IGF‐I) assays in comparison to the former Nichols Advantage IGF‐I in a growth hormone treated population
  publication-title: Clin Chem Lab Med
– start-page: 165
  year: 2007
  end-page: 181
– volume: 151
  start-page: 385
  year: 1988
  end-page: 418
  article-title: Fitting smoothed centile curves to reference data
  publication-title: J R Stat Soc Ser A Stat Soc
– volume: 51
  start-page: 37
  year: 2014
  end-page: 43
  article-title: Demystifying LMS and BCPE methods of centile estimation for growth and other health parameters
  publication-title: Indian Pediatr
– volume: 64
  start-page: 68
  year: 2005
  end-page: 76
  article-title: IGF‐I and IGF binding protein‐3 levels during initial GH dosage step‐up are indicators of GH sensitivity in GH‐deficient children and short children born small for gestational age
  publication-title: Horm Res
– volume: 61
  start-page: 335
  year: 2006
  end-page: 339
  article-title: Variability among five different commercial IGF‐1 immunoassays in conditions of childhood‐onset GH deficiency and GH therapy
  publication-title: Acta Clin Belg
– volume: 15
  start-page: 1
  issue: Suppl 2
  year: 2009
  end-page: 29
  article-title: American association of clinical endocrinologists medical guidelines for clinical practice for growth hormone use in growth hormone‐deficient adults and transition patients ‐ 2009 update
  publication-title: Endocr Pract
– volume: 44
  start-page: 45
  year: 1990
  end-page: 60
  article-title: The LMS method for constructing normalized growth standards
  publication-title: Eur J Clin Nutr
– volume: 161
  start-page: S33
  issue: Suppl 1
  year: 2009
  end-page: S39
  article-title: The value of IGF1 estimation in adults with GH deficiency
  publication-title: Eur J Endocrinol
– volume: 99
  start-page: 1712
  year: 2014
  end-page: 1721
  article-title: Reference intervals for insulin‐like growth factor‐1 (igf‐i) from birth to senescence: results from a multicenter study using a new automated chemiluminescence IGF‐I immunoassay conforming to recent international recommendations
  publication-title: J Clin Endocrinol Metab
– volume: 81
  start-page: 1371
  year: 1996
  end-page: 1377
  article-title: Monitoring of growth hormone replacement therapy in adults, based on measurement of serum markers
  publication-title: J Clin Endocrinol Metab
– volume: 29
  start-page: 6
  year: 2007
  end-page: 13
  article-title: Statistical methods for constructing gestational age‐related reference intervals and centile charts for fetal size
  publication-title: Ultrasound Obstet Gynecol
– volume: 23
  start-page: 1749
  year: 2004
  end-page: 1765
  article-title: A comparison of goodness of fit tests for age‐related reference ranges
  publication-title: Stat Med
– volume: 19
  start-page: 457
  year: 2009
  end-page: 462
  article-title: The first international standard for insulin‐like growth factor‐1 (IGF‐1) for immunoassay: preparation and calibration in an international collaborative study
  publication-title: Growth Horm IGF Res
– volume: 98
  start-page: 761
  year: 2013
  end-page: 768
  article-title: IGF‐I bioactivity might reflect different aspects of quality of life than total IGF‐I in GH‐deficient patients during GH treatment
  publication-title: J Clin Endocrinol Metab
– volume: 55
  start-page: 100
  issue: Suppl 2
  year: 2001
  end-page: 105
  article-title: Normal values of insulin‐like growth factor I and their clinical utility in adults
  publication-title: Horm Res
– volume: 167
  start-page: 647
  year: 2008
  end-page: 653
  article-title: Reference levels for 17‐hydroxyprogesterone, 11‐desoxycortisol, cortisol, testosterone, dehydroepiandrosterone sulfate and androstenedione in infants from birth to six months of age
  publication-title: Eur J Pediatr
– volume: 60
  start-page: 53
  year: 2003
  end-page: 60
  article-title: Serum insulin‐like growth factor I reference values for an automated chemiluminescence immunoassay system: results from a multicenter study
  publication-title: Horm Res
– volume: 95
  start-page: 2089
  year: 2010
  end-page: 2098
  article-title: Variable degree of growth hormone (GH) and insulin‐like growth factor (IGF) sensitivity in children with idiopathic short stature compared with GH‐deficient patients: evidence from an IGF‐based dosing study of short children
  publication-title: J Clin Endocrinol Metab
– volume: 163
  start-page: 180
  year: 2012
  end-page: 184
  article-title: Normal serum anti‐Mullerian hormone levels in the general female population and the relationship with reproductive history
  publication-title: Eur J Obstet Gynecol Reprod Biol
– volume: 71
  start-page: 30
  issue: Suppl 1
  year: 2009
  end-page: 33
  article-title: Pitfalls of insulin‐like growth factor I assays
  publication-title: Horm Res
– volume: 11
  start-page: 1305
  year: 1992
  end-page: 1319
  article-title: Smoothing reference centile curves: the LMS method and penalized likelihood
  publication-title: Stat Med
– volume: 70
  start-page: 163S
  year: 1999
  end-page: 165S
  article-title: Curve smoothing and transformations in the development of growth curves
  publication-title: Am J Clin Nutr
– volume: 100
  start-page: 309
  year: 2015
  end-page: 316
  article-title: The introduction of the IDS‐iSYS total IGF‐1 assay may have far‐reaching consequences for diagnosis and treatment of GH deficiency
  publication-title: J Clin Endocrinol Metab
– volume: 44
  start-page: 27
  year: 2015
  end-page: 34
  article-title: Pitfalls of insulin‐like growth factor‐i and growth hormone assays
  publication-title: Endocrinol Metab Clin North Am
– volume: 83
  start-page: 3913
  year: 1998
  end-page: 3919
  article-title: Optimizing growth hormone replacement therapy by dose titration in hypopituitary adults
  publication-title: J Clin Endocrinol Metab
– volume: 57
  start-page: 555
  year: 2011
  end-page: 559
  article-title: Consensus statement on the standardization and evaluation of growth hormone and insulin‐like growth factor assays
  publication-title: Clin Chem
– volume: 40
  start-page: 1093
  year: 2007
  end-page: 1099
  article-title: Reference values for serum levels of insulin‐like growth factor (IGF‐1) and IGF‐binding protein 3 (IGFBP‐3) and their ratio in Chinese adolescents
  publication-title: Clin Biochem
– volume: 92
  start-page: 298
  year: 2007
  end-page: 303
  article-title: Blood pressure centiles for Great Britain
  publication-title: Arch Dis Child
– ident: e_1_2_6_15_1
  doi: 10.1210/jc.2016-1257
– ident: e_1_2_6_29_1
  doi: 10.1093/ajcn/70.1.163s
– ident: e_1_2_6_13_1
  doi: 10.1016/j.ghir.2009.02.002
– ident: e_1_2_6_14_1
  doi: 10.1210/jc.2013-3059
– ident: e_1_2_6_26_1
  doi: 10.1136/adc.2005.081216
– volume: 167
  start-page: 647
  year: 2008
  ident: e_1_2_6_24_1
  article-title: Reference levels for 17‐hydroxyprogesterone, 11‐desoxycortisol, cortisol, testosterone, dehydroepiandrosterone sulfate and androstenedione in infants from birth to six months of age
  publication-title: Eur J Pediatr
  doi: 10.1007/s00431-007-0565-1
– ident: e_1_2_6_12_1
  doi: 10.1373/clinchem.2010.150631
– ident: e_1_2_6_28_1
  doi: 10.1007/s13312-014-0310-6
– ident: e_1_2_6_33_1
  doi: 10.1002/uog.3911
– ident: e_1_2_6_32_1
  doi: 10.1002/sim.4780111005
– ident: e_1_2_6_9_1
  doi: 10.1210/jcem.83.11.5223
– ident: e_1_2_6_8_1
  doi: 10.1210/jc.81.4.1371
– volume: 61
  start-page: 335
  year: 2006
  ident: e_1_2_6_10_1
  article-title: Variability among five different commercial IGF‐1 immunoassays in conditions of childhood‐onset GH deficiency and GH therapy
  publication-title: Acta Clin Belg
  doi: 10.1179/acb.2006.053
– ident: e_1_2_6_25_1
  doi: 10.1016/j.clinbiochem.2007.06.004
– ident: e_1_2_6_3_1
  doi: 10.1016/j.ecl.2014.10.003
– start-page: 165
  volume-title: Growth Disorders, 2007
  year: 2007
  ident: e_1_2_6_27_1
– ident: e_1_2_6_6_1
  doi: 10.1210/jc.2009-2139
– ident: e_1_2_6_34_1
  doi: 10.1111/j.1471-0528.1994.tb13006.x
– ident: e_1_2_6_17_1
  doi: 10.1210/jc.2012-2901
– volume: 44
  start-page: 45
  year: 1990
  ident: e_1_2_6_21_1
  article-title: The LMS method for constructing normalized growth standards
  publication-title: Eur J Clin Nutr
– ident: e_1_2_6_4_1
  doi: 10.1159/000063484
– ident: e_1_2_6_5_1
  doi: 10.1530/EJE-09-0247
– ident: e_1_2_6_18_1
  doi: 10.4158/EP.15.S2.1
– ident: e_1_2_6_7_1
  doi: 10.1159/000087692
– ident: e_1_2_6_2_1
  doi: 10.1159/000178034
– ident: e_1_2_6_19_1
  doi: 10.1159/000071871
– ident: e_1_2_6_31_1
  doi: 10.2307/2982992
– ident: e_1_2_6_22_1
  doi: 10.1002/sim.1692
– volume: 100
  start-page: 309
  year: 2015
  ident: e_1_2_6_16_1
  article-title: The introduction of the IDS‐iSYS total IGF‐1 assay may have far‐reaching consequences for diagnosis and treatment of GH deficiency
  publication-title: J Clin Endocrinol Metab
  doi: 10.1210/jc.2014-2558
– ident: e_1_2_6_11_1
  doi: 10.1515/CCLM.2008.349
– ident: e_1_2_6_23_1
  doi: 10.1016/j.ejogrb.2012.04.013
– ident: e_1_2_6_30_1
  doi: 10.1002/sim.2227
– ident: e_1_2_6_20_1
  doi: 10.1507/endocrj.K09E-200
SSID ssj0005807
Score 2.3029177
Snippet Summary Introduction and Background Normative data for the iSYS IGF‐I assay have been published both in the VARIETE cohort and by Bidlingmaier et al. Objective...
Normative data for the iSYS IGF-I assay have been published both in the VARIETE cohort and by Bidlingmaier et al. To investigate whether normative data of the...
Summary Introduction and Background Normative data for the iSYS IGF-I assay have been published both in the VARIETE cohort and by Bidlingmaier et al. Objective...
Normative data for the iSYS IGF-I assay have been published both in the VARIETE cohort and by Bidlingmaier et al.INTRODUCTION AND BACKGROUNDNormative data for...
SourceID proquest
pubmed
crossref
wiley
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 409
SubjectTerms clinical interpretation
GH deficiency
Growth hormones
IGF‐I
Insulin-like growth factor I
LMS method
normative data
Physical growth
Title Disagreement in normative IGF‐I levels may lead to different clinical interpretations and GH dose adjustments in GH deficiency
URI https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fcen.13491
https://www.ncbi.nlm.nih.gov/pubmed/28977695
https://www.proquest.com/docview/2002169920
https://www.proquest.com/docview/1947620481
Volume 88
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVWIB
  databaseName: Wiley Online Library - Core collection (SURFmarket)
  issn: 0300-0664
  databaseCode: DR2
  dateStart: 19970101
  customDbUrl:
  isFulltext: true
  eissn: 1365-2265
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0005807
  providerName: Wiley-Blackwell
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LS-wwFA7i4uJGvT7HF1FcuOnQNmnacleijqOgC1FwIZSkSWB0budiOoJ35U-4v_H-Ek_Sh44PEHehTZs0J6fnO8k5XxDaDUlMdcR9T4M59WhOfU-IVHgk5BrcBR3Eic13Pjtn_St6eh1dT6FfTS5MxQ_RLrhZzXD_a6vgXJhXSp6romu59azrExDm3KmLF-qoqE6VJjZzmjFaswrZKJ72yUlb9A5gTuJVZ3B6c-im6WoVZ3LXHZeim_99w-L4zW-ZR7M1EMX71cz5iaZUsYB-nNVb7Yvo6XBgODjjbvkQDwpcVOj2QeGT497_p38neGgDjgz-zR-hyCUuR7g5b6XETcolHkyENRrMC4mP-1iOjMJc3o6Ni3M3tgl7WVlKC5sPuoSuekeXB32vPq7BywlosieY5hLkzIkKiZRUxZxbAnlJdKQ1ODKMUK0AohClwjTXgQDZqJRIXyZBzCKyjKaLUaFWEQ4IF34gwcDGjAqiEpkDbmEiEjSQwpcdtNcILstrLnN7pMYwa3waGNHMjWgH7bRV_1QEHh9V2mikn9U6bDIXvsLSNPQ7aLu9Ddpnt1R4oUZjkwUpjS2jfwKvWKlmTdsKuLJxzNIIOutk_3nz2cHRuSusfb3qOpoB7JZU4XAbaLq8H6tNwEel2HKK8Awg8Av6
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB5VRQIuvCkLBQziwCWrJHacROoFlW53obsH1Eq9oMiObWmhZBHJIsGpP4HfyC_pjPOA5SEhblbixI7Hk_nGnvkM8CzmqXCJCgOH5jQQpQgDrXMd8Fg5dBdclGaU7zxfyOmJeHWanG7BXp8L0_JDDAtupBn-f00KTgvSP2l5aasxkeuh73NJSPRTCBK9-UEelXTJ0pxyp6UUHa8QxfEMj25ao98g5iZi9SZnch3e9p1tI03ej9eNHpdff-Fx_N-vuQHXOizKXrST5yZs2eoWXJ53u-234fzlslboj_sVRLasWNUC3M-WzQ4n38-_zdgZxRzV7IP6gkVlWLNi_ZErDeuzLtlyI7KxZqoy7HDKzKq2TJl369qHutfUBF22xGpBKaF34GRycLw_DboTG4KSozIHWjplUNSK25gbI2yqFHHIG-4S59CXkVw4iyiFWxvnpYs0Csfm3IQmi1KZ8LuwXa0qew9YxJUOI4M2NpVCc5uZEqGL1IkWkdGhGcHzXnJF2dGZ06kaZ0Xv1uCIFn5ER_B0qPqx5fD4U6XdXvxFp8Z14SNYZJ7H4QieDLdRAWlXRVV2ta6LKBcpkfpn-IqddtoMraA3m6YyT7CzXvh_b77YP1j4wv1_r_oYrkyP50fF0Wzx-gFcRSiXtdFxu7DdfFrbhwiXGv3Ia8UF4D4QGw
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NTtwwEB4hKiEu9A_oUtq6VQ9cskpix0mkXiqWZRfKqkIgcUGRHdvStksWNdlK7YlH6DP2STp2ftpti4S4WYkTOx5P5ht75jPA25DGzETC9wyaU4_lzPekTKVHQ2HQXTBBnNh855MJH52zo4voYgXetbkwNT9Et-BmNcP9r62C62tl_tDyXBd9S66Hvs8DFqWJDegbnP4mj4qaZGlqc6c5Zw2vkI3j6R5dtkb_QMxlxOpMzvAhXLadrSNNPvcXlezn3__icbzv1zyCjQaLkvf15HkMK7p4AmsnzW77U7gZTEuB_rhbQSTTghQ1wP2qyfhw-PPmx5jMbMxRSa7ENywKRao5aY9cqUibdUmmS5GNJRGFIocjoualJkJ9WpQu1L20TdjL2rJa2JTQTTgfHpztj7zmxAYvp6jMnuRGKBS1oDqkSjEdC2E55BU1kTHoy3DKjEaUQrUO09wEEoWjU6p8lQQxj-gWrBbzQj8DElAh_UChjY05k1QnKkfowmUkWaCkr3qw10ouyxs6c3uqxixr3Roc0cyNaA_edFWvaw6P_1XabcWfNWpcZi6Chadp6PfgdXcbFdDuqohCzxdlFqQstqT-Cb5iu542XSvozcYxTyPsrBP-7c1n-wcTV9i5e9VXsPZxMMw-jCfHz2EdkVxSB8ftwmr1ZaFfIFqq5EunFL8AcrAPnw
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Disagreement+in+normative+IGF-I+levels+may+lead+to+different+clinical+interpretations+and+GH+dose+adjustments+in+GH+deficiency&rft.jtitle=Clinical+endocrinology+%28Oxford%29&rft.au=Varewijck%2C+AJ&rft.au=van+der+Lely%2C+AJ&rft.au=Neggers%2C+SJCMM&rft.au=Hofland%2C+LJ&rft.date=2018-03-01&rft.pub=Wiley+Subscription+Services%2C+Inc&rft.issn=0300-0664&rft.eissn=1365-2265&rft.volume=88&rft.issue=3&rft.spage=409&rft_id=info:doi/10.1111%2Fcen.13491&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0300-0664&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0300-0664&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0300-0664&client=summon